


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-64. Canceled

65. (Previously presented) A compound of formula I,



wherein

R^1 represents Het^1 , $\text{R}^{1a}\text{C}(\text{O})-$ or $\text{D}-\text{A}-\text{N}(\text{H})-[\text{Q}]_n-\text{C}(\text{O})-\text{E}-\text{C}(\text{O})-$;

R^{1a} represents

H,

aryl (which latter group is optionally substituted by one or more substituents selected from OH, halo, cyano, nitro, $\text{N}(\text{R}^{3a})\text{R}^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy), aromatic or part-aromatic C_{13-14} tricyclic carbocyclyl (which latter group is optionally substituted by one or more substituents selected from OH, halo, cyano, nitro, $\text{N}(\text{R}^{3a})\text{R}^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy, and which latter group, if part-aromatic, is optionally substituted in the non-aromatic part by one or two oxo groups) or

C_{1-12} alkyl (which latter group is optionally substituted and/or terminated by one or more substituents selected from halo and aryl (which latter group is optionally substituted by one or more substituents selected from OH, halo, cyano, nitro, $\text{N}(\text{R}^{3a})\text{R}^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy)); A represents, at each occurrence when used herein, C_{2-6} alkylene or $\text{A}^1-\text{C}(\text{O})\text{N}(\text{H})-\text{A}^2$, wherein A^2 is attached to the group D;

A^1 represents C_{1-4} alkylene;

A^2 represents C_{2-5} alkylene;


D represents, at each occurrence when used herein, $-N(R^{2a})R^{2b}$, $-C(=NR^{2c})N(R^{2d})R^{2e}$ or $-N(R^{2f})C(=NR^{2g})N(H)R^{2h}$;

R^{2a} and R^{2b} independently represent H, C_{1-6} alkyl, Het² or R^{2a} and R^{2b} together represent $(CH_2)_3$, which alkylene group is optionally interrupted by NR^4 and/or is optionally substituted by one or more C_{1-4} alkyl groups;

R^4 represents H, C_{1-6} alkyl or Het³;

R^{2c} to R^{2h} independently represent H or C_{1-6} alkyl;

E represents $-E^1-Het^4-$, E^{2a} , $-(CH_2)_{0-3}N(H)C(O)-E^{2b}-C(O)N(H)(CH_2)_{0-3}-$ or a structural fragment of the formula



wherein E^3 represents $(CH_2)_{1-2}$, $CH=CH$, $CH=N$, $CH_2-N(R^a)$, $(CH_2)_{0-1}C(O)$, $(CH_2)_{0-1}O$ or $(CH_2)_{0-1}S$;

R^a represents H or C_{1-6} alkyl;

E^1 represents $(CH_2)_{0-2}$ or $CH=CH$;

E^{2a} and E^{2b} independently represent C_{2-4} alkenylene, C_{3-6} cycloalkylene, phenylene or naphthylene;


Het¹ to Het⁴ independently represent four- to twelve-membered heterocyclic groups containing one or more heteroatoms selected from N, O and S, which heterocyclic groups are optionally substituted by one or more substituents selected from $=O$, OH , halo, cyano, nitro, $N(R^{3a})R^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy;

R^{3a} and R^{3b} independently represent, at each occurrence when used herein, H or C_{1-4} alkyl, or R^{3a} represents $-C(O)R^5$;


R^5 represents H or C_{1-4} alkyl;

n represents, at each occurrence when used herein, 2, 3, 4 or 5;


each individual Q independently represents a structural fragment of formula Ia, Ib, Ic, Id, Ie or If




Ia




Ib




Ic



Id



Ie



If

wherein

R⁶ represents H or C₁₋₆ alkyl;

R⁷ represents C₁₋₁₂ alkyl;

R⁸, R⁹, R¹⁰ and R¹¹ independently represent H or C₁₋₁₂ alkyl;

G represents CH or N;

L represents O or S;

p, q and r independently represent 0, 1, 2 or 3; and

provided that the compound comprises at least one structural fragment of formula Ib, Ic, Id, Ie or If in which R^6 or R^7 , R^8 , R^9 , R^{10} or R^{11} , respectively, represents branched, cyclic or part cyclic C_{3-5} alkyl; or a pharmaceutically acceptable derivative thereof.

66. (Previously presented) A compound as claimed in Claim 65, wherein:

R^{1a} represents H or C_{1-12} alkyl, which latter group is optionally substituted and/or terminated by one or more substituents selected from halo and aryl, which latter group is optionally substituted by one or more substituents selected from OH, halo, cyano, nitro, $N(R^{3a})R^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy; and

the compound comprises at least one structural fragment of formula Ib, Ic, Id, Ie or If in which R^7 , R^8 , R^9 , R^{10} or R^{11} , respectively, represents branched, cyclic or part cyclic C_{3-5} alkyl.

67. (Previously presented) A compound as claimed in Claim 65, wherein aryl is phenyl or naphthyl.


68. (Previously presented) A compound as claimed in Claim 65, wherein alkyl and alkoxy groups are, where appropriate:

- (a) straight-chain;
- (b) branched-chain and/or cyclic; or
- (c) part cyclic/acyclic.

69. (Previously presented) A compound as claimed in Claim 65, wherein alkyl and alkoxy groups are, where appropriate:

- (a) saturated or unsaturated;
- (b) interrupted by one or more oxygen and/or sulfur atoms; and/or
- (c) unless otherwise specified, substituted by one or more halo atoms.

70. (Previously presented) A compound as claimed in Claim 65, which is a compound of formula II,



wherein

R^1 represents Het^1 , $\text{R}^{1a}\text{C(O)-}$ or $\text{D-A-N(H)-Q}^3\text{-Q}^2\text{-Q}^1\text{-C(O)-E-C(O)-}$;

Q^1 is absent or represents a structural fragment of formula Ia, Ib, Ic, Id, Ie or If;

Q^2 represents a structural fragment of formula Ib, Ie or If;

Q^3 represents a structural fragment of formula Ib, Id, Ie or If; and

Het^1 , R^{1a} , D, A, E, R^{2a} , R^{2b} , A and the structural fragments of formulae Ia, Ib, Ic, Id, Ie and If are as defined in any one of Claims 16 to 20; provided that:

(a) at least one of Q^1 , Q^2 and Q^3 represents a structural fragment of formula Id, Ie or If; and

(b) at least one of R^6 or R^7 , R^8 , R^9 , R^{10} and R^{11} (whichever is/are present) represents branched, cyclic or part cyclic C_{3-5} alkyl, or a pharmaceutically acceptable derivative thereof.

71. (Previously presented) A compound as claimed in Claim 65, wherein the compound comprises:

(a) at least one structural fragment of formula Ib in which G represents N and R^6 represents branched, cyclic or part cyclic C_{3-5} alkyl;


(b) at least one structural fragment of formula Id in which p represents 0 and R^9 represents branched, cyclic or part cyclic C_{3-5} alkyl; and/or

(c) at least one structural fragment of formula Ie in which q represents 0 and R^{10} represents branched, cyclic or part cyclic C_{3-5} alkyl.

72. (Previously presented) A compound as claimed in Claim 65, wherein each of the at least one branched, cyclic or part cyclic C_{3-5} alkyl groups independently represents isopropyl, cyclopropylmethyl, isopentyl or cyclopentyl.


73. (Previously presented) A compound as claimed in Claim 65, wherein the compound comprises at least one structural fragment of formula Ib, Ic, Id, Ie or If in which R^7 , R^8 , R^9 , R^{10} or R^{11} , respectively, represents isopropyl.

74. (Previously presented) A compound as claimed in Claim 65, which compound comprises at least one structural fragment of the formula



75-94. (Canceled)

95. (New) A compound of formula IIa,



wherein

R¹ represents

A nine-membered aromatic heterocycle containing two heteroatoms selected from N, O and S,

R^{1a}C(O)- or

D-A-N(H)-Q³-Q²-Q¹-C(O)-E-C(O)-;

R^{1a} represents

H

Phenyl (which latter group is optionally substituted by C₁₋₂ alkoxy),

9,10-dioxo-9,10-dihydroanthracenyl (which latter group is optionally substituted by C₁₋₂ alkoxy),

saturated, optionally branched C₁₋₆ alkyl or

saturated C₁₋₃ *n*-alkyl, which latter group is terminated by phenyl (which latter group is optionally substituted by C₁₋₂ alkoxy);

A represents saturated C₂₋₄ alkylene or (CH₂)₁₋₃-C(O)N(H)-(CH₂)₂₋₄;

D represents -N(R^{2a})R^{2b};

R^{2a} and R^{2b} independently represent

C₁₋₃ alkyl or a nine- or ten-membered aromatic heterocycle containing one to three heteroatoms selected from N, O and S, or

R^{2a} and R^{2b} together represent (CH₂)₃₋₅, which alkylene group is optionally interrupted by NR⁴;

R⁴ represents

C₁₋₃ alkyl or a non- or tem-membered aromatic heterocycle containing one to three heteroatoms selected from N, O and S;

E represents

-(2,5-indolyl)-,

-(CH₂)₀₋₂-(2,6-indolyl)-,

-CH=CH-(2,6-indolyl)-,


trans-ethenylene,

trans-cyclopropylene,

1,3- or 1-4-phenylene,

-CH₂N(H)C(O)-(1,3- or 1,4-phenylene)-C(O)N(H)CH₂-,

or one of the following structural fragments




Q¹ is absent or represents a structural fragment of formula Ia, Ib, Ic, Id, Ie or If;


Q² represents a structural fragment of formula Ib, Ie or If;

Q³ represents a structural fragment of formula Ib, Id, Ie or If;


wherein the structural fragments of formulae Ia, Ib, Ic, Id, Ie and If are as follows




Ia




Ib




Ic



Id



Ie



If

wherein

R^6 represents H or, when G represents N, R^6 may also represent branched, cyclic or part cyclic C_{3-5} alkyl;


R^7 , R^8 , R^9 , R^{10} and R^{11} independently represent saturated, optionally branched C_{1-6} alkyl or R^8 represents H;

provided that the compound comprises at least one structural fragment of formula Ie in which R^{10} represents branched, cyclic or part cyclic C_{3-5} alkyl.

96. (New) A compound as claimed in Claim 95 wherein the compound comprises at least one structural fragment of formula Ie in which R¹⁰ represents cyclopropylmethyl, isopentyl, cyclopentyl or isopropyl.

97. (New) A compound as claimed in Claim 95 wherein the compound comprises at least one structural fragment of formula Ie in which R¹⁰ represents isopropyl.

98. (New) A compound of formula IIb,



wherein

R¹ represents

a nine-membered aromatic heterocycle containing two heteroatoms selected from N, O and S,

HC(O)-,

(methoxyphenyl)C(O)-,

(9,10-dioxo-9,10-dihydroanthracenyl)C(O)-,

(saturated C₁₋₃ alkyl) C(O)-,

(methoxyphenylacetyl)C(O)-, or

(CH₃)₂N-A-N(H)-Q³-Q²-Q¹-C(O)-E-C(O)-;

A represents saturated C₂₋₄ *n*-alkylene or (CH₂)₂-C(O)N(H)-(CH₂)₃;


E represents -CH₂N(H)C(O)-(1,3-phenylene)-C(O)N(H)CH₂-;

Q¹ is absent or represents a structural fragment of formula Ia, Ib, Ic, Id, Ie or If;

Q² represents a structural fragment of formula Ib, Ie or If;

Q³ represents a structural fragment of formula Ib, Id, Ie or If;

wherein the structural fragments of formulae Ia, Ib, Ic, Id, Ie and If are as follows



wherein

R^6 represents H or, when G represents N, R^6 may also represent branched, cyclic or part cyclic C_{3-5} alkyl;

R^7 , R^9 , R^{10} and R^{11} independently represent saturated, optionally branched C_{1-3} alkyl;

provided that the compound comprises at least one structural fragment of formula Ie in which R^{10} represents branched, cyclic or part cyclic C_{3-5} alkyl.

99. (New) A compound as claimed in Claim 98, wherein the compound comprises at least one structural fragment of formula Ie in which R^{10} represents cyclopropylmethyl, isopentyl, cyclopentyl or isopropyl.

100. (New) A compound as claimed in Claim 98, wherein the compound comprises at least one structural fragment of formula 1e in which R¹⁰ represents isopropyl.

101. (New) A compound as claimed in Claim 65, which compound is selected from the following:

(i) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1-*H*-pyrrol-3-yl]-4-[(3,3-dimethylbutanoyl)amino]-1-methyl-1*H*-pyrrole-2-carboxamide;

(ii) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1-*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(iii) *N*-[3-(Dimethylamino)propyl]-2-({[4-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}amino)-1-methyl-1-*H*-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide;

(iv) *N*-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopropyl-1-*H*-pyrrol-3-yl]-4-({[4-(formylamino)-1-isopropyl-1-*H*-pyrrol-2-yl]carbonyl}-amino)-1-isopropyl-1-*H*-pyrrole-2-carboxamide

(v) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopentyl-1-*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1-*H*-pyrrol-3-yl]-4-(formyl-amino)-1-isopentyl-1-*H*-pyrrole-2-carboxamide;

(vi) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopropyl-1-*H*-pyrrol-3-yl]amino}carbonyl)-1-methyl-1-*H*-pyrrol-3-yl]-4-(formyl-amino)-1-isopropyl-1-*H*-pyrrole-2-carboxamide;

(vii) *N*-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1-*H*-pyrrol-3-yl]-2-({[4-(formylamino)-1-methyl-1-*H*-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide;

(viii) 4-({[4-(Formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl} amino)-1-iso-propyl-*N*-[1-methyl-5-({[3-(4-morpholinyl)propyl]amino} carbonyl)-1*H*-pyrrol-3-yl]-1*H*-pyrrole-2-carboxamide;

(ix) 4-(Formylamino)-*N*-[1-isopropyl-5-({[1-methyl-5-({[3-(1-pyrrolidinyl)-propyl]amino} carbonyl)-1*H*-pyrrol-3-yl]amino} carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(x) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino} carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino} carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(xi) 2-(Acetylamino)-*N*-[5-({[5-({[3-(dimethylamino)propyl]amino}-carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino} carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide;

(xii) 2-(Acetylamino)-*N*-[5-({[4-({[3-(dimethylamino)propyl]amino}-carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino} carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide;

(xiii) 2-(Acetylamino)-*N*-(5-({[3-({[3-(dimethylamino)propyl]amino}-3-oxo-propyl)amino]carbonyl}-1-methyl-1*H*-pyrrol-3-yl)-5-isopropyl-1,3-thiazole-4-carboxamide;

(xiv) *N*¹,*N*³-Bis(2-({[5-({[4-({[3-(dimethylamino)propyl]amino} carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino} carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-amino}-2-oxoethyl)isophthalamide;

(xv) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino} carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino} carbonyl)-1-isopropyl-1*H*-pyrrol-3-yl]-4-(acetyl-amino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(xvi) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino} carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino} carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-(acetyl-amino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(xvii) *N*²,*N*⁵-Bis[5-({[4-({[3-(dimethylamino)propyl]amino} carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino} carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(xviii) N^2, N^5 -Bis[1-isopentyl-5-({[1-methyl-5-({[3-(4-morpholinyl)propyl]-amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(xix) N^2, N^5 -Bis[5-({[5-({[3-(dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(xx) N^2, N^5 -Bis[1-isopentyl-5-({[1-methyl-5-({[3-(4-methyl-1-piperazinyl)-propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(xxi) 2-({[4-({[4-(Acetylamino)-1-methyl-1*H*-imidazol-2-yl]carbonyl}-amino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}amino)-*N*-[3-(dimethylamino)-propyl]-5-isopropyl-1,3-thiazole-4-carboxamide;

(xxii) 4-(Acetylamino)-*N*-[1-isopentyl-5-({[1-methyl-5-({[3-(4-methyl-1-piperazinyl)propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxiii) *N*-[1-Isopentyl-5-({[1-methyl-5-({[3-(4-methyl-1-piperazinyl)-propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxiv) *N*-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-4-({[5-(formylamino)-2-methyl-3-thienyl]carbonyl}amino)-1-isopentyl-1*H*-pyrrole-2-carboxamide;

(xxv) *N*-[5-({[5-({[3-(dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-5-isopropyl-2-[(3-methoxybenzoyl)amino]-1,3-thiazole-4-carboxamide;

(xxvi) *N*-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-4-[[5-({[(9,10-dioxo-9,10-dihydro-2-anthracenyl)carbonyl]-amino}-2-methyl-3-thienyl)carbonyl]amino]-1-isopentyl-1*H*-pyrrole-2-carboxamide;

(xxvii) *N*-[1-(Cyclopropylmethyl)-5-({[5-({[3-(dimethylamino)propyl]amino} carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino} carbonyl)-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxviii) 1-Cyclopentyl-*N*-[5-({[3-(dimethylamino)propyl]amino} carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-4-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]-carbonyl}-amino)-1*H*-pyrrole-2-carboxamide;

(xxix) *N*²,*N*⁷-Bis[5-({[4-({[3-(dimethylamino)propyl]amino} carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino} carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-9,10-dihydro-2,7-phenanthrenedicarboxamide;

(xxx) 4-(Formylamino)-*N*-[1-isopentyl-5-({[1-methyl-5-({[3-(4-methyl-1-piperazinyl)propyl]amino} carbonyl)-1*H*-pyrrol-3-yl]amino} carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxxi) 4-(Acetylamino)-*N*-[1-isopentyl-5-({[1-methyl-5-({[3-(4-morpholinyl)propyl]amino} carbonyl)-1*H*-pyrrol-3-yl]amino} carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxxii) 4-(Formylamino)-*N*-[1-isopentyl-5-({[1-methyl-5-({[3-(4-morpholinyl)propyl]amino} carbonyl)-1*H*-pyrrol-3-yl]amino} carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxxiii) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino} carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino} carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1*H*-pyrrole-2-carboxamide; and

(xxxiv) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino} carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino} carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-[(4-methoxyphenyl)acetyl] amino}-1-methyl-1*H*-pyrrole-2-carboxamide.

102. (New) A compound as claimed in Claim 101 which is:

(a) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(b) *N*-[3-(Dimethylamino)propyl]-2-({[4-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}amino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide;

(c) *N*-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-2-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide;

(d) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(e) *N*²,*N*⁵-Bis[1-isopentyl-5-({[1-methyl-5-({[3-(4-morpholinyl)propyl]-amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(f) *N*-[1-(Cyclopropylmethyl)-5-({[5-({[3-(dimethylamino)propyl]-amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide; or

(g) *N*²,*N*⁷-Bis[5-({[4-({[3-(dimethylamino)propyl]amino}carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-9,10-dihydro-2,7-phenanthrenedicarboxamide.

103. (New) A compound as claimed in Claim 95 which is *N*-[3-(dimethylamino)-propyl]-2-({[4-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}amino)-5-isopropyl-1,3-thiazole-4-carboxamide.

104. (New) A compound as claimed in Claim 65, which binds to and/or has specificity for DNA sequences that contain at least one GC base pairing.

105. (New) A compound as claimed in Claim 104, which is:

- (i) a compound of formula I, as defined in any one of Claims 95-97 provided that the compound comprises at least one structural fragment of formula Id, Ie or If; or
- (ii) a compound of formula II, as defined in any one of Claims 98-101.

106. (New) A compound as claimed in Claim 65 which has different binding affinities at different minor groove binding sites in double-stranded DNA molecules having more than one minor groove binding site.

107. (New) A compound as claimed in Claim 106, wherein the different minor groove binding sites comprise solely AT base pairs.

108. (New) A pharmaceutical formulation including a compound as defined in Claim 65 in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.

109. (New) A method of treatment of a disease that relies upon DNA replication for its propagation, which method comprises administration of a therapeutically effective amount of a compound as defined in Claim 65 to a person suffering from that disease.

110. (New) A method of treatment of cancer, which method comprises administrations of a therapeutically effective amount of a compound as defined in Claim 65 to a person suffering from cancer.

111. (New) A method of treatment of a viral, bacterial, fungal or other microbial infection, which method comprises administration of a therapeutically effective amount of a compound as defined in Claim 65 to a person suffering from such an infection.

112. (New) A method of treating a viral, bacterial, fungal or other microbial (e.g. parasitic) infection, where the viral, bacterial, fungal or other microbial (e.g. parasitic) infective agent is resistant to one or more anti-viral, anti-bacterial, anti-fungal or other anti-microbial (e.g. anti-parasitic) agents, respectively, that do not act by inhibiting DNA replication, which method comprises administration of a therapeutically effective amount of a compound as defined in Claim 65 to a person having that infection.

113. (New) A method of treatment of a disease that relies upon DNA replication for its propagation, which method comprises administration, to a person suffering from that disease, of a therapeutically effective amount of a compound as defined in Claim 65 in combination with one or more other agents that are known to be effective in treating that disease.

114. (New) A combination product comprising components:
(A) a formulation comprising a compound as defined in Claim 65; and
(B) a formulation comprising one or more other chemical agents that are known to be effective in treating diseases that rely upon DNA replication for their propagation.

115. (New) A combination product as claimed in Claim 114, wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.

116. (New) A combination product as claimed in Claim 114, wherein (A) and (B) are presented as separate components.

117. (New) A combination product as claimed in Claim 114, wherein (A) and (B) are presented as a single formulation.


118. (New) A method of inhibiting DNA replication, which method comprises contacting the DNA with an inhibitory amount of a compound as defined in Claim 65.

119. (New) A method of stabilising a DNA duplex formed between first and second single strands of DNA, which method comprises contacting that DNA duplex with a compound as defined in Claim 65.


120. (New) A method of enhancing the difference in melting temperatures between first and second DNA duplexes, wherein each DNA duplex is formed from a first single strand of DNA that is the same in each duplex and a second single strand of DNA that is different in each duplex, which method comprises contacting each DNA duplex with a compound as defined in Claim 65.

121. (New) A process for the preparation of compounds of formula I as defined in Claim 65 which comprises:

(a) reaction of a compound of formula III,




wherein A^a represents A or, when a represents 0, then A^a may also represent A^2 and Q, D, A and A^2 are as defined in Claim 16 and a is as defined below, with a compound of formula IV,




wherein A^b represents a direct bond or $-\text{A}^1-\text{C}(\text{O})-$, as appropriate, L^1 represents a leaving group, a and b both represent integers from 0 to 5, the sum of the two being 2, 3, 4 or 5, and R^1 and Q are as defined in Claim 65;

(b) for compounds of formula I in which R¹ represents D-A-N(H)-[Q]_n-C(O)-E-C(O)-, reaction of two equivalents of a compound of formula V,



wherein Q, n, A and D are as defined in Claim 65, with a compound of formula VI,



wherein L² represents a leaving group, the two L² groups being the same or different, and E is as defined in Claim 65; or

(c) deprotection of a protected derivative of a compound of formula I as defined in Claim 65.

122. (New) A compound of formula V, as defined in Claim 121, or a protected derivative thereof.